Prime Medicine, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Prime Medicine, Inc. (PRME) had Deferred Tax Assets, Operating Loss Carryforwards of $116.78 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-03
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $116.78M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $61.50M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $35.98M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $20.43M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $116.78M 10-K · filed 2026-03-03 |
| 2024-12-31 | $61.50M 10-K · filed 2026-03-03 |
| 2023-12-31 | $35.98M 10-K · filed 2025-02-28 |
| 2022-12-31 | $20.43M 10-K · filed 2024-03-01 |
| 2021-12-31 | $11.37M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |